Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Immunotherapy Toxicities.

Sanchez K, Page DB, Urba W.

Surg Oncol Clin N Am. 2019 Jul;28(3):387-401. doi: 10.1016/j.soc.2019.02.009. Epub 2019 Apr 5. Review.

PMID:
31079795
2.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
3.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD.

Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018.

4.

Ambulatory oxygen and quality of life in interstitial lung disease.

Page DB, Thannickal VJ.

Lancet Respir Med. 2018 Oct;6(10):730-731. doi: 10.1016/S2213-2600(18)30337-0. Epub 2018 Aug 28. No abstract available.

PMID:
30170903
5.

Thirty-day hospital readmissions among mechanically ventilated emergency department patients.

Page DB, Drewry AM, Ablordeppey E, Mohr NM, Kollef MH, Fuller BM.

Emerg Med J. 2018 Apr;35(4):252-256. doi: 10.1136/emermed-2017-206651. Epub 2018 Jan 5.

PMID:
29305381
6.

Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.

Page DB, Wen H, Brogi E, Dure D, Ross D, Spinelli KJ, Patil S, Norton L, Hudis C, McArthur HL.

Breast Cancer Res Treat. 2018 Jan;167(2):547-554. doi: 10.1007/s10549-017-4520-1. Epub 2017 Oct 6.

PMID:
28986743
7.

Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score.

Mariotti V, Page DB, Davydov O, Hans D, Hudis CA, Patil S, Kunte S, Girotra M, Farooki A, Fornier MN.

J Bone Oncol. 2016 Oct 18;7:32-37. doi: 10.1016/j.jbo.2016.10.004. eCollection 2017 Jun.

8.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

Pianko MJ, Funt SA, Page DB, Cattry D, Scott EC, Ansell SM, Borrello IM, Gutierrez M, Lendvai N, Hassoun H, Landgren CO, Lesokhin AM.

Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30. No abstract available.

9.
10.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.

11.

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.

Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL.

Cancer Immunol Res. 2016 Oct;4(10):835-844. Epub 2016 Sep 1. Erratum in: Cancer Immunol Res. 2017 Mar;5(3):269.

12.

What does the future hold for immunotherapy in cancer?

Naidoo J, Li BT, Schindler K, Page DB.

Ann Transl Med. 2016 May;4(9):177. doi: 10.21037/atm.2016.04.05. No abstract available.

13.

Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine.

Page DB, Hulett TW, Hilton TL, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2016 May 17;4:25. doi: 10.1186/s40425-016-0130-4. eCollection 2016. Review.

14.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD.

Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12. No abstract available.

15.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.

16.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

17.

Inability of Physicians and Nurses to Predict Patient Satisfaction in the Emergency Department.

DeLaney MC, Page DB, Kunstadt EB, Ragan M, Rodgers J, Wang HE.

West J Emerg Med. 2015 Dec;16(7):1088-93. doi: 10.5811/westjem.2015.9.28177. Epub 2015 Dec 14.

18.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD.

Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14. Review. Erratum in: Ann Oncol. 2016 Jul;27(7):1362.

19.

Community-, Healthcare-, and Hospital-Acquired Severe Sepsis Hospitalizations in the University HealthSystem Consortium.

Page DB, Donnelly JP, Wang HE.

Crit Care Med. 2015 Sep;43(9):1945-51. doi: 10.1097/CCM.0000000000001164.

20.

CTLA-4 antibodies: new directions, new combinations.

Funt SA, Page DB, Wolchok JD, Postow MA.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:6-14. Review.

21.

Immune modulation for cancer therapy.

Naidoo J, Page DB, Wolchok JD.

Br J Cancer. 2014 Dec 9;111(12):2214-9. doi: 10.1038/bjc.2014.348. Epub 2014 Sep 11. Review.

22.

Immune checkpoint blockade.

Naidoo J, Page DB, Wolchok JD.

Hematol Oncol Clin North Am. 2014 Jun;28(3):585-600. doi: 10.1016/j.hoc.2014.02.002. Review.

PMID:
24880949
23.

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.

Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, Wong P, Wu X, Naidoo J, Page DB, Wolchok JD, Hodi FS.

Cancer Immunol Res. 2014 Feb;2(2):127-32. doi: 10.1158/2326-6066.CIR-13-0163.

24.

Emerging immunotherapy strategies in breast cancer.

Page DB, Naidoo J, McArthur HL.

Immunotherapy. 2014;6(2):195-209. doi: 10.2217/imt.13.166. Review.

PMID:
24491092
25.

Immune modulation in cancer with antibodies.

Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD.

Annu Rev Med. 2014;65:185-202. doi: 10.1146/annurev-med-092012-112807. Epub 2013 Oct 30. Review.

PMID:
24188664
26.

Checkpoint modulation in melanoma: an update on ipilimumab and future directions.

Page DB, Postow MA, Callahan MK, Wolchok JD.

Curr Oncol Rep. 2013 Oct;15(5):500-8. doi: 10.1007/s11912-013-0337-1. Review.

27.

Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.

Page DB, Yuan J, Wolchok JD.

Immunotherapy. 2010 May;2(3):367-79. doi: 10.2217/imt.10.21. Review.

PMID:
20635901
28.

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.

Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD.

Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951.

29.

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD.

Cancer Immun. 2010 Jan 7;10:1. Erratum in: Cancer Immun. 2010 Feb 24;10:5. Ritter, Erika [added].

30.

A computerized survey of pain in Parkinson's disease patients: A pilot feasibility study.

Page DB, Weaver F, Wilkie DJ, Simuni T.

Parkinsonism Relat Disord. 2010 Feb;16(2):139-41. doi: 10.1016/j.parkreldis.2009.07.001. Epub 2009 Jul 28.

PMID:
19640770

Supplemental Content

Support Center